ライフサイエンスコーパス: extraprostatic

1 ul in identifying disease (1 prostate bed, 3 extraprostatic).

2 expressed prostatic secretions from men with extraprostatic and organ-confined prostate cancers ident

3 tivity than (18)F-FDG for intraprostatic and extraprostatic cancer detection.

4 nd 1994, 1369 non-stage A1 and 423 advanced (extraprostatic) cases of prostate cancer were diagnosed.

5 e cancer (excluding stage A1), 419 advanced (extraprostatic) cases, and 200 metastatic cases.

6 0.06-4.6) ng/mL, 56 of 86 patients (65%) had extraprostatic disease (pT3), 39 of 86 (45%) had a Gleas

7 Patients with palpable extraprostatic disease (T3) have a poor prostate-specifi

8 isease (pT2) (1477 of 2160; 68%), those with extraprostatic disease at MRI (102 of 1477; 7%) were at

9 d better outcomes than those with concordant extraprostatic disease at MRI and pathologic analysis: 1

10 between organ-confined tumors and those with extraprostatic disease extension.

11 rther, alternative modalities of determining extraprostatic disease must be investigated beyond the c

12 ate in the differentiation of prostatic from extraprostatic disease.

13 e of at least 7, or radiographic evidence of extraprostatic disease.

14 ivity of this pathway may be selected by the extraprostatic environment or, as supported by our data,

15 5% CI: 1.2, 2.1; P = .003); and suspicion of extraprostatic extension (EPE) (HR, 2.18; 95% CI: 1.1, 4

16 Conclusion Higher MRI-based extraprostatic extension (EPE) grading categories were a

17 tures associated with pathologically defined extraprostatic extension (EPE) of prostate cancer and to

18 1.6; P < .001), SVR (OR, 6.2; P = .02), and extraprostatic extension (EPE) scores of 2 (OR, 9.3; P <

19 There were 1,370 patients (56%) with extraprostatic extension (EPE), 452 (18%) with seminal v

20 Accuracy in determining the location, extraprostatic extension (EPE), and seminal vesicle inva

21 predicted larger tumor volumes (P < 0.001), extraprostatic extension (P = 0.003), and seminal vesicl

22 = 7 (P =.036 and P =.020, respectively) and extraprostatic extension (P =.047).

23 Extraprostatic extension and seminal vesicle invasion we

24 ession of the proliferation marker Ki-67 and extraprostatic extension of the tumor.

25 In the detection of extraprostatic extension of transition zone cancers, sen

26 (kappa = 0.266-0.439); and fair for definite extraprostatic extension on T2-weighted images (kappa =

27 was associated with cancers characterized by extraprostatic extension or distant metastases (stage C

28 Men with high-risk features (extraprostatic extension or high Gleason grade) face a h

29 ely selected patients with positive margins, extraprostatic extension or seminal vesicle invasion, bu

30 ry, European Society of Urogenital Radiology extraprostatic extension score, nodes) fitted to the tra

31 vesicle invasion, positive surgical margins, extraprostatic extension) and salvage radiotherapy with

32 and Data System score, index lesion burden, extraprostatic extension, and preoperative guided biopsy

33 nical stage, Gleason score, surgical margin, extraprostatic extension, and seminal vesicle invasion,

34 reoperative prostate-specific antigen (PSA), extraprostatic extension, and total tumor volume.

35 in patients with either positive margins or extraprostatic extension, its effect on cause-specific m

36 inical and pathologic findings (grade group, extraprostatic extension, nodal involvement) relevant fo

37 ith pathologically advanced prostate cancer (extraprostatic extension, positive surgical margins, or

38 progression, as APCs exhibit lower rates of extraprostatic extension, seminal vesical invasion and l

39 thological features including Gleason score, extraprostatic extension, status of surgical margins, an

40 pecific antigen level greater than 10 ng/mL, extraprostatic extension, tumor volume more than 20%, ca

41 n the right lobe of the prostate without any extraprostatic extension.

42 imary Gleason 4 or any Gleason 5 disease, or extraprostatic extension.

43 gan-confined disease, and 20 (70%) of 30 had extraprostatic extension; 11 (37%) of the 30 had positiv

44 There were no incidental extraprostatic findings on PET suggestive of metastatic

45 state, including bed and seminal vesicle, or extraprostatic, including all lymph nodes, bone, or soft

46 Earlier detection of extraprostatic invasion and metastases by means of radio

47 .4%, and 70.3% for the lesion, prostate, and extraprostatic levels, respectively, with associated Fle

48 or recurrent disease in the prostate bed and extraprostatic locations.

49 l surface protein with limited expression in extraprostatic normal tissues.

50 ween the primary NE tumor and lesions in the extraprostatic organs.

51 Among patients with histopathologic extraprostatic (pT3) disease (683 of 2160; 32%), those w

52 In the detection of extraprostatic recurrence, anti-3-(18)F-FACBC had a sens

53 e region; and 83.3%, 75.0%, and 83.3% in the extraprostatic region for readers 1, 2, and 3, respectiv

54 Intra- and extraprostatic seed locations could be distinguished.

55 The most common extraprostatic site of seed implantation was the neurova

56 The most common extraprostatic tissue finding was increased signal inten

57 Of the 74 extraprostatic tissue specimens that were resected, 22 (

58 hibits only limited expression in benign and extraprostatic tissues, and thus represents an ideal tar

59 um and prostate cancer as well as in several extraprostatic tissues.

60 mental lineage, arising from either intra or extraprostatic tumour cell populations, at early and lat

61 h nodes originate from evolutionary advanced extraprostatic tumour cells rather than less advanced ce